Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding the role of Jazz Pharma's Vyxeos (cytarabine and daunorubicin liposome for injection) in the AML treatment space

Ticker(s): JAZZ

Who's the expert?

Name: Dr Gabriel Ghiaur - MD

Institution: Johns Hopkins University

  • Medical oncologist affiliated with the Sidney Kimmel Comprehensive Cancer Center and an assistant professor at Johns Hopkins University.
  • Currently manages 80-100 patients per year with AML; sees 50 new patients a year out of 300 in his group.
  • Physician-scientist whose primary interest is normal and malignant hematopoiesis; research has translational potential in stem cell therapeutics, as well as acute leukemia.

Interview Questions

Please describe your current practice. How many patients do you currently treat with AML?

Added By: c_admin

How do you stratify your AML patients  ( young patients versus greater than 60, patients who are fit, or unfit). How you're currently treating those patient groups?

Added By: c_admin

Is there anything else that you think is relevant in terms of treatments on the horizon that you're very excited about?

Added By: c_admin

On a scale of 1-10, where would you rate your level of excitement for Vyxeos with 10 being very excited?

Added By: c_admin

Do you think doctors will restrict usage of Vyxeos to the trial population (older than 60) or will they use it with younger patients as well?

Added By: joe_mccann

What do you think was driving the survival benefit in the Vyxeos trial?

Added By: joe_mccann

What are some of the unanswered questions in your mind in terms of the granularity around that data? What would you like to see and learn when the full data is published?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.